News

Novo Nordisk A/S confirmed on 6 August that sales growth for the year is expected to be between 8 and 14% at constant exchange rates while the increase in operating profit is expected to amount to 10 to 16%, also at constant exchange rates. This confirms an announcement on 29 July and is considerably lower than the projection in May, reflecting a reassessment of the business outlook for the rest of the year when demand for the company’s obesity and diabetes products is expected to be less robust. 

Merck & Co Inc’s $10 billion acquisition of Verona Pharma Plc is set to close in the 2025 fourth quarter marking one of the larger transactions in the biopharma space in recent times. The deal will give Merck a recently approved asset for chronic obstructive pulmonary disease (COPD) that is on a promising trajectory. When Merck announced its offer on 9 July, some share analysts were already predicting blockbuster status for the asset, Ohtuvayre (ensifentrine), which was approved by the US Food and Drug Administration on 26 June 2024.

The European Commission has expressed confidence that a recent trade agreement between the EU and US will provide stability and predictability for the two parties even as the full details are still to be worked out. In a briefing for journalists on 7 August, a Commission spokesperson said the agreement is the best result possible given the challenging circumstances. This is because it creates a uniform tariff of 15% across multiple product groups, down from an initial 30% demanded by the US.

argenx SE continued to build momentum towards its goal of treating 50,000 patients with its medicines by 2030 as both its pipeline and clinical development activities increased. By 30 June, the company’s lead product Vyvgart (efgartigimod), which was first approved in 2021, had already achieved three approved indications, and the company was conducting or making plans for registrational studies for two other products.

Sanofi SA has become the latest European pharma company to retreat from the consumer healthcare business in order to focus on proprietary drug development. On 30 April it divested its controlling stake in Opella, one of the world’s largest producers of over-the-counter medicines, to the private equity group Clayton, Dubilier & Rice – a deal that generated €10 billion in cash for the French company whilst still leaving it with a 48.2% interest. Bpifrance, the French public investment bank, holds the remaining 1.8%.

AstraZeneca Plc gave its strongest endorsement yet of the US as a centre for life science innovation with the publication of second quarter results on 29 July. These showed a double-digit increase in revenue of which 44% was generated from the US. Speaking to journalists on the same day, Pascal Soriot, the chief executive, said market size, favourable prices, and a strong research environment made the US a prime investment location.

US-based MapLight Therapeutics Inc has raised $372.5 million in a Series D financing to advance its portfolio of drugs for central nervous system disorders. Announced on 28 July, the deal was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives and stands out as one of the larger private financings of the year. It will support ongoing Phase 2 clinical trials in schizophrenia and Alzheimer’s disease psychosis, a condition that is estimated to affect 40% of people with the disease.

GSK Plc has confirmed its sales target of £40 billion for 2031 following a second quarter of higher turnover for its specialty medicines and vaccines. The forecast is based on the sales trajectory of recently launched products as well as new ones poised for market entry. For 2025 the company expects sales to increase towards the top end of a 3% to 5% range. 

Abivax SA has secured new financing of up to $747.5 million from a public offering of American Depositary Shares (ADSs) in the wake of two successful Phase 3 trial results for a small molecule drug for ulcerative colitis. Both trials achieved clinical remissions for a significant number of patients. The offering was initially announced on 23 July with the intention of raising $400 million. But after the trial results were reported, the company’s shares experienced a five-fold increase in value.

The Roche Group continued to face generic competition for its legacy cancer medicines in the first half of 2025, but this was overtaken by double-digit sales increases for some of its newest products and regulatory approvals for several others. At the same time, the disease coverage of the company’s portfolio broadened. Group sales in the first half were CHF 30.9 billion ($33.11 billion), up by 4% in Swiss francs and by 7% in constant exchange rates. The pharmaceuticals division, which accounts for 78% of group sales, generated CHF 24 billion while diagnostics produced CHF 7 billion.